Literature DB >> 32933341

Attenuation of Bleomycin-Induced Pulmonary Fibrosis in Wistar Rats by Combination Treatment of Two Natural Phenolic Compounds: Quercetin and Gallic Acid.

Saeed Mehrzadi1, Pooyan Hosseini2, Mehrnaz Mehrabani3, Amir Siahpoosh2, Mehdi Goudarzi2, Hamidreza Khalili4, Alireza Malayeri2,4.   

Abstract

The present study aimed to investigate the protective effects of two potent natural antioxidants, gallic acid and quercetin as single or combination treatment against bleomycin-induced pulmonary fibrosis (PF). A total of 50 Wistar rats were randomly divided into 5 groups. Group 1 and 2 intratracheally received saline and bleomycin (7.5 UI/kg), respectively, on day 7, accompanied by oral saline administration for 28 day. Groups 3, 4, and 5 received a single dose of bleomycin on day 7, accompanied by oral administration of gallic acid, quercetin, and their combination, respectively, for 28 day. Finally, the lungs were removed for biochemical and histopathological tests. The combination treatment demonstrated a remarkable decrease in lung hydroxyproline and TNF-α level and increase in catalase activity as compared with both single phytochemical-treated groups. The combination treatment significantly enhanced lung SOD activity and GSH level and decreased NO and IL-6 levels as compared with quercetin-treated group. However, only combination treatment could decrease the lung index and completely reversed histopathological changes in the bleomycin-treated group. In sum, when compared to a single exposure, the combination treatment might be a more effective approach for PF treatment because of its superior efficacy in reversing lung histological changes in the bleomycin-treated group.

Entities:  

Year:  2020        PMID: 32933341     DOI: 10.1080/01635581.2020.1820053

Source DB:  PubMed          Journal:  Nutr Cancer        ISSN: 0163-5581            Impact factor:   2.900


  5 in total

1.  Bioavailability Enhancement of Cepharanthine via Pulmonary Administration in Rats and Its Therapeutic Potential for Pulmonary Fibrosis Associated with COVID-19 Infection.

Authors:  Jian Li; Guangrui Chen; Zhiyun Meng; Zhuona Wu; Hui Gan; Xiaoxia Zhu; Peng Han; Taoyun Liu; Fanjun Wang; Ruolan Gu; Guifang Dou
Journal:  Molecules       Date:  2022-04-24       Impact factor: 4.927

2.  Mechanism of Fei-Xian Formula in the Treatment of Pulmonary Fibrosis on the Basis of Network Pharmacology Analysis Combined with Molecular Docking Validation.

Authors:  Xiao-Li Chen; Cheng Tang; Qing-Ling Xiao; Zhong-Hua Pang; Dan-Dan Zhou; Jin Xu; Qi Wang; Ya-Xi Zhao; Qi-Yong Zhu
Journal:  Evid Based Complement Alternat Med       Date:  2021-08-03       Impact factor: 2.629

Review 3.  Targeting Oxidative Stress as a Therapeutic Approach for Idiopathic Pulmonary Fibrosis.

Authors:  Cristina Estornut; Javier Milara; María Amparo Bayarri; Nada Belhadj; Julio Cortijo
Journal:  Front Pharmacol       Date:  2022-01-21       Impact factor: 5.810

Review 4.  Natural Product-Based Potential Therapeutic Interventions of Pulmonary Fibrosis.

Authors:  Mahbub Hasan; Nidhan Chandra Paul; Shamrat Kumar Paul; Abu Saim Mohammad Saikat; Hafeza Akter; Manoj Mandal; Sang-Suk Lee
Journal:  Molecules       Date:  2022-02-22       Impact factor: 4.411

5.  Effect of red osier dogwood extract on growth performance, blood biochemical parameters, and gut functionality of broiler chickens challenged or unchallenged intraperitoneally with Salmonella Enteritidis lipopolysaccharide.

Authors:  Taiwo J Erinle; Janice MacIsaac; Chengbo Yang; Deborah I Adewole
Journal:  Poult Sci       Date:  2022-03-18       Impact factor: 4.014

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.